AstraZeneca commits to CRISPR gene-editing collaboration
AstraZeneca has joined up with academic and industrial research partners to use CRISPR, a new and much-hyped gene-editing technology in their quest for new medicines....
The industrial application of biological processes and living organisms to make products for human use, especially in medicine, agriculture and food science.
AstraZeneca has joined up with academic and industrial research partners to use CRISPR, a new and much-hyped gene-editing technology in their quest for new medicines....
Biogen Idec has made an investment deal to develop gene therapy treatments for haemophilia A and B....
by James Brooks
Does the pharmaceutical and biotech industry's profit motive actually pervert rather than inspire innovation and the hunt for new therapies? Is the patent system well suited to a new life sciences landscape including stem cell and gene therapies?...
by Alice Plein
Pathway Genomics, a biotech company based in San Diego, announced it will 'vigorously defend itself' against a patent infringement suit filed by Myriad Genetics and others...
The backdrop to the third event in the Progress Educational Trust's 'Breast Cancer: Chances, Choices and Genetics' series was the Myriad Genetics gene patenting legal saga, which came to a conclusion last year with Myriad being denied a patent on the isolated forms of the BRCA genes...
The European Commission has rejected a petition requesting a stop to the funding of research involving the 'presupposed destruction' of human embryos....
A system that allows researchers to control a tiny cellular transport network has been developed by researchers at the Universities of Oxford and Warwick...
The Children's Hospital of Philadelphia has invested US $50 million in a biotech start-up in an effort to commercialise gene therapy...
A new genetic test that can estimate the risk of breast cancer in women returning after surgery has been approved for use in the NHS....
A highly anticipated experimental treatment for the genetic condition Duchenne Muscular Dystrophy has failed in a key test of its effectiveness in a critical phase III clinical trial.
BioNews, published by the Progress Educational Trust (PET), provides news and comment on genetics, assisted conception, embryo/stem cell research and related areas.